Medicare Part D users would pay higher prices for some new drugs for an extra four years.
This bill, called the Next GEN Act, would change how long certain new drugs are protected from price negotiations under Medicare. Specifically, it would give drug makers an extra four years before some "engineered cyclic peptide" drugs could have their prices negotiated. This means people on Medicare Part D would likely pay more for these specific drugs for a longer time.
Today, most new single-source drugs are eligible for price negotiation under Medicare's Drug Price Negotiation Program after 7 years. If this bill passes, certain "engineered cyclic peptide" drugs would not be eligible for price negotiation until 11 years after their approval, an increase of 4 years. The bill also clearly defines what an "engineered cyclic peptide" is.
HR 8857 · 119th Congress · May 15, 2026 · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers